Poniard Pharmaceuticals (PARD) 0.00 0.02

Poniard Pharmaceuticals, Inc.
(PARD) 0.00 0.02

Last Trade:	1.02	Day Range:	0.85 - 1.02
Trade Time:	08:02PM	52wk Range:	0.71 - 1.45
Prev. Close:	1.00	Market Cap:	1.53M
Open:	0.85	Div Yield:	0
Volume:	960	PE:	-0
EPS:	-12.00

The Latest On PARD

UPDATE: Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board 1/3/12 8:12am

Microcap Movers For Friday November 18, 2011 11/19/11 3:05pm

Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology 11/18/11 8:30am

ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 11/9/11 8:32am

Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 11/7/11 8:32am

Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 10/28/11 7:33am

Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares 9/6/11 7:42am

Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares 9/6/11 7:41am

Poniard Pharmaceuticals Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal 7/11/11 10:51am

Poniard Pharmaceuticals Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Reverse Stock Split Proposal 7/5/11 7:32am

Poniard Pharmaceuticals Surges On Merger News With Allozyne 6/22/11 4:05pm

UPDATE: Poniard Pharmaceuticals Resumes Trading; Up Over 35% 6/22/11 3:59pm

UPDATE: Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board 1/3/12

Microcap Movers For Friday November 18, 2011 11/19/11

Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology 11/18/11

ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 11/9/11

Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 11/7/11

Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split 10/28/11

Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares 9/6/11

Poniard Pharmaceuticals Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal 7/11/11

Poniard Pharmaceuticals Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Reverse Stock Split Proposal 7/5/11

Poniard Pharmaceuticals Surges On Merger News With Allozyne 6/22/11

UPDATE: Poniard Pharmaceuticals Resumes Trading; Up Over 35% 6/22/11

Benzinga’s Top Pre-Market Losers (PARD, DLTR, GENZ, SNDA, ACOR, TTHI, HCBK) 1/25/10

Interesting Trade in Poniard 12/3/09

Benzinga’s Top Pre- Market Gainers (VVUS, PARD, CSUN, SOLF, NLST, ASMI, CAKE) 11/18/09

Biggest Losers (CAEI, TBV, PARD, CRXX, HOOK, ADY) 11/16/09

Benzinga’s Top Pre- Market Losers (CADC, TIBX, PARD, HGSI, SHPGY, ATVI) 11/16/09

Poniard Pharmaceuticals Inc (NASDAQ:PARD) Highest Implied Volatility 11/13/09

Benzinga’s Top Downgrades (STP, STJ, GPC, PARD) 1/25/10

Trade PARD
NOW!

Partner Headlines

Poniard Pharmaceuticals Inc. Reports Operating Results (10-Q) 10/28/11

5 Health Care Stocks With Upside 3/21/11

Stocks Under $5 With the Most Sell Ratings 6/24/10

Poniard, Xfone: Early Volume Plays 3/24/10

Cell Therapeutics, Zoom Technologies: Midday Volume Plays 3/8/10

Medivation: Biotech Stock Mailbag 3/3/10

Bonus Biotech Stock Mailbag: Medivation 3/3/10

Press Releases

PARL, PARD and CGFIA are the Daily Market Movers for December 27th from OTCPicks.com 12/27/11 Emailwire Story

PARD, EVCA, PRPH, FTWR, HPGS and CRPZ are the Daily Market Movers for November 18th from OTCPicks.com 11/18/11 Emailwire Story

Get the latest PARD stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Poniard Pharmaceuticals, Inc. stock price.

Poniard Pharmaceuticals, Inc. by YCharts